This episode delves into the critical reimbursement gap facing innovative medical devices in the United States. We explore why FDA Breakthrough Device designation doesn't guarantee Medicare payment, the financial "valley of death" this creates for MedTech startups, and how the proposed "Ensuring Patient Access to Critical Breakthrough Products Act" aims to provide a vital four-year bridge of temporary coverage.

- What is the FDA's Breakthrough Devices Program?

- Why does FDA approval not automatically lead to Medicare reimbursement?

- What is the "reimbursement valley of death" for MedTech innovators?

- How does the evidence required by the FDA differ from that required by CMS?

- What was the MCIT rule and why was its 2021 repeal significant?

- What is the "Ensuring Patient Access to Critical Breakthrough Products Act"?

- How does the proposed four-year transitional coverage period work?

- Why is this legislation critical for medical innovation and patient access?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient pathways for regulatory approval, leveraging advanced AI to compile and submit technical dossiers that minimize rejections. Our experts act as your local representative in over 30 markets, helping you identify the best regions for expansion and ensuring your innovative products reach patients faster. Whether you are a startup or a multinational enterprise, our technology-driven solutions are tailored to your needs. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools at https://pureglobal.ai.